Decreased REST Levels Linked to Alzheimer's Disease Pathology Are Improved by NAD+
Overview
This study identifies that reduced REST expression and altered localization contribute to Alzheimer's disease pathology. It demonstrates that NAD+ via the SIRT1 pathway modulates REST expression, improving cognition and reducing amyloid-β and phosphorylated Tau deposition.
Background
Alzheimer's disease (AD) is characterized by progressive cognitive decline associated with amyloid-β plaques and neurofibrillary tangles composed of phosphorylated Tau. REST, a transcriptional repressor, is downregulated in AD and is implicated in healthy aging and neuroprotection. Mitochondrial dysfunction and impaired mitophagy are key contributors to AD progression, with NAD+ and SIRT1 playing critical roles in maintaining mitochondrial and neuronal health.
Data Highlights
REST expression and sub-cellular localization were examined across Braak stages in the entorhinal cortex and hippocampus. REST overexpression improved cognition and reduced amyloid-β and phosphorylated Tau deposition. NAD+ supplementation elevated SIRT1 levels, which modulated REST expression via chromatin remodeling, restoring mitochondrial and synaptic homeostasis.
Key Findings
REST levels are decreased in the entorhinal cortex and hippocampus in Alzheimer's disease, correlating with disease progression.
Overexpression of REST improves cognitive function and reduces amyloid-β and phosphorylated Tau accumulation.
The NAD+/SIRT1 axis regulates REST expression through chromatin remodeling at the REST promoter.
REST modulates genes involved in mitophagy and synaptic function, contributing to mitochondrial and synaptic homeostasis.
NAD+ supplementation restores REST levels and mitigates AD pathology in experimental models.
Clinical Implications
Targeting the NAD+/SIRT1/REST pathway offers a promising therapeutic strategy to slow or reverse Alzheimer's disease progression. Enhancing REST expression through NAD+ supplementation may improve mitochondrial function and reduce pathological protein accumulation, potentially preserving cognitive function in AD patients.
Conclusion
This study elucidates a novel mechanism by which NAD+ modulates REST expression to counteract Alzheimer's disease pathology, highlighting REST as a viable therapeutic target for AD intervention.
References
Original Article 2024 -- Decreased REST Levels Linked to Alzheimer's Disease Pathology Are Improved by NAD+
